Cybin to Host Q2 2025 Financial Results and Business Update Conference Call

Cybin Inc. announced it will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The company, which describes itself as a late-stage breakthrough neuropsychiatry company, is focused on revolutionizing mental healthcare through developing new and innovative next-generation treatment options. This update comes at a critical juncture as the company advances multiple clinical programs targeting significant mental health conditions where current treatment options remain limited.

The announcement comes as Cybin continues developing its pipeline of investigational compounds targeting mental health conditions. The company is currently advancing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development timeline. The designation represents a significant regulatory milestone that could expedite the availability of new treatment options for patients suffering from depression.

Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in a Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting various mental health conditions where current treatment options remain limited. Investors and interested parties can access the full press release at https://ibn.fm/BqH38 for complete details about the upcoming conference call. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.

The upcoming financial results presentation and business update will provide stakeholders with important insights into Cybin's progress in developing potential breakthrough treatments for major depressive disorder and generalized anxiety disorder, conditions that affect millions of people worldwide and represent significant market opportunities for innovative pharmaceutical approaches. These developments are particularly important given the growing recognition of mental health as a global health priority and the need for more effective, durable treatment options beyond traditional pharmaceutical approaches.